Table 3. Pathological details.
| Variables | Unmatched groups | Matched groups | |||||
|---|---|---|---|---|---|---|---|
| T-RAMIE (N=144) | H-RAMIE (N=70) | P value | T-RAMIE (N=49) | H-RAMIE (N=49) | P value | ||
| Histology | 0.585 | NA | |||||
| Squamous cell carcinoma | 139 (96.5) | 67 (95.7) | 49 (100.0) | 49 (100.0) | |||
| Adenocarcinoma | 1 (0.7) | 2 (2.9) | 0 | 0 | |||
| Adenosquamous carcinoma | 1 (0.7) | 0 | 0 | 0 | |||
| Adenoidcystic carcinoma | 1 (0.7) | 0 | 0 | 0 | |||
| Melanoma | 1 (0.7) | 1 (1.4) | 0 | 0 | |||
| GIST | 1 (0.7) | 0 | 0 | 0 | |||
| Pathological stage | 0.020 | 0.025 | |||||
| 0 | 7 (4.9) | 0 | 4 (8.2) | 0 | |||
| I | 13 (9.0) | 14 (20.0) | 7 (14.3) | 6 (12.3) | |||
| IA | 8 (5.6) | 4 (5.7) | 4 (8.2) | 3 (6.1) | |||
| IB | 54 (37.5) | 12 (17.1) | 15 (30.6) | 10 (20.4) | |||
| IIA | 9 (6.3) | 5 (7.1) | 4 (8.2) | 3 (6.1) | |||
| IIB | 10 (6.9) | 12 (17.1) | 3 (6.1) | 8 (16.3) | |||
| IIIA | 15 (10.4) | 8 (11.4) | 5 (10.2) | 7 (14.3) | |||
| IIIB | 15 (10.4) | 10 (14.3) | 5 (10.2) | 7 (14.3) | |||
| IVA | 8 (5.6) | 4 (5.7) | 2 (4.0) | 4 (8.2) | |||
| IVB | 2 (1.4) | 1 (1.4) | 0 | 1 (2.0) | |||
| Number of harvested LNs | 48.1±22.6 | 46.2±19.7 | 0.545 | 45.0±22.2 | 45.4±21.5 | 0.936 | |
| Cervical LNs | 9.2±14.1 | 6.6±12.1 | 0.165 | 7.8±13.0 | 6.2±12.7 | 0.488 | |
| Mediastinal LNs | 25.6±10.6 | 26.6±11.6 | 0.552 | 24.2±10.3 | 26.5±11.8 | 0.375 | |
| Abdominal LNs | 13.0±9.0 | 12.9±8.1 | 0.899 | 12.4±9.0 | 12.3±8.9 | 0.992 | |
T-RAMIE, totally robot-assisted minimally invasive esophagectomy; H-RAMIE, hybrid robot-assisted minimally invasive esophagectomy; LN, lymph node; GIST, gastrointestinal stromal tumor.